Ursula Kees Fellow, CLCRF; Co-head, Leukaemia and Cancer Genetics
PhD
Areas of research expertise: Genetics, Molecular biology, Animal models, Preclinical studies
Dr Sébastien Malinge is a Senior Research Fellow highly qualified in the field of paediatric leukaemia, with a strong background in the mechanisms of leukaemia predisposition and development in children with Down syndrome. He obtained his PhD in 2006 from the Necker-Enfants Malades Hospital (Paris children's hospital, France) and was subsequently awarded a prestigious research fellowship by the Leukaemia and Lymphoma Society to join Northwestern University (Chicago, USA). In 2012, following his post-doctoral training, he further developed his research projects as an independent investigator at the French National Institute for Health and Medical Research (INSERM), located at the first Cancer Centre in Europe, the Gustave Roussy Institute. In 2017, Dr Malinge relocated to the Telethon Kids Institute as the Children`s Leukaemia and Cancer Research Foundation (CLCRF) fellow, to co-lead the West Australian Paediatric Leukaemia and Cancer Genetics preclinical research program within the Telethon Kids Cancer Centre.
Based on a solid background in fundamental research, next generation sequencing and the development of preclinical Patient Derived Xenograft (PDX) models, Dr Malinge is now developing cutting-edge approaches to unravel new vulnerabilities in leukaemia cells, with the view of identifying alternative therapeutic approaches and new effective treatments, to make a tangible difference to the way we treat paediatric leukaemia.
In the news:
Find Sèbastien Malinge on Google Scholar and ORCID.
-
Projects
-
Publications
November 2020
The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution
The bone marrow microenvironment (BMM) plays a key role in leukemia progression, but its molecular complexity in pre-B cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children, remains poorly understood. To gain further insight, we used single-cell RNA sequencing to characterize the kinetics of the murine BMM during B-ALL progression.
Children's Cancers Published research Leukaemia and Cancer Genetics Subsite: CancerAugust 2020SNAIL trail in myeloid malignancies
Transcription factors known to induce the epithelial-to-mesenchymal transition (EMT) (such as ZEB1/2 [zinc finger E-box binding homeobox 1/2], SNAI1/2/3, and TWIST1/2) have been undoubtedly implicated in tumorigenesis, cancer progression, metastasis, and chemoresistance in solid tumors; however, their role in normal and malignant hematopoiesis has been underappreciated for many years.
Children's Cancers Published research Leukaemia and Cancer GeneticsJuly 2019Romidepsin enhances the efficacy of cytarabine in vivo, revealing HDAC inhibition as a therapeutic strategy for KMT2A-rearranged acute lymphoblastic leukemia
In this study, we investigate the in vivo synergy between romidepsin and cytarabine
Children's Cancers Published research Leukaemia and Cancer GeneticsNovember 2018A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis
Here we report that CHAF1B is required for normal hematopoiesis while its overexpression promotes leukemia
Children's Cancers Published research Leukaemia and Cancer GeneticsJuly 2018Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models
This JAK3A572V knockin model is a relevant new tool for testing the efficacy of JAK inhibitors in JAK3-related hematopoietic malignancies
Children's Cancers Published research Leukaemia and Cancer Genetics -
Education & Qualifications
-
Awards/Honours